Quick answer: latest quarter results, by ticker or company name

Reported Q: Q4 2024 Rev YoY: N/A EPS YoY: +118.4% Move: -1.35%

Genor Biopharma Holdings

6998.HK

HKD2.93 -1.35%

Exchange HKSE Sector Healthcare Industry Biotechnology

Q4 2024

Published: Dec 31, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for 6998.HK

Reported

Report Date

Dec 31, 2024

Quarter Q4 2024

Revenue

95.88M

YoY: N/A

EPS

0.07

YoY: +118.4%

Market Move

-1.35%

Previous quarter: Q3 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $95.88M up 0% year-over-year
EPS of $0.07 increased by 118.4% from previous year
Gross margin of 99.5%
Net income of 37.21M
"N/A" - N/A

6998.HK

Company 6998.HK

Period Q4 2024

Currency CNY

Report Type Quarterly Earnings

Generated Feb 11, 2026

Executive Summary

Genor Biopharma reported QQ4 2024 revenue of 95,879,500 CNY, delivering a remarkably high gross margin of 99.48% and an operating income of 28,762,000 CNY. Net income for the quarter was 37,206,000 CNY with an EPS of 0.0719 CNY, supported by a substantial contribution from other income (total other income/expenses net of 17,455,000 CNY) that lifted income before tax to 46,217,000 CNY. EBITDA stood at 41,516,250 CNY, underscoring strong quarterly profitability propelled by a favorable revenue mix and a lean cost of revenue (cost of revenue of 496,000 CNY). The quarter’s bottom line benefited from non-operating items, indicating a financing or miscellaneous income tailwind rather than a solely core-operating performance driver.

Key Performance Indicators

Revenue

Stable

95.88M

QoQ: 0.00% | YoY: N/A

Gross Profit

Stable

95.38M

99.48% margin

QoQ: 0.00% | YoY: N/A

Operating Income

Increasing

28.76M

QoQ: 0.00% | YoY: 113.85%

Net Income

Increasing

37.21M

QoQ: 0.00% | YoY: 118.61%

EPS

Increasing

0.07

QoQ: 0.00% | YoY: 118.44%

Revenue Trend

Margin Analysis

Financial Highlights

Revenue: 95,879,500 CNY (QoQ: 0.00% as reported for QQ4 2024 vs QQ3 2024). Gross Profit: 95,383,500 CNY; Gross Margin: 99.48%. Operating Income: 28,762,000 CNY; Operating Margin: 29.99%. EBITDA: 41,516,250 CNY; EBITDA Margin: 43.30%. Net Income: 37,206,000 CNY; Net Margin: 38.80%. EPS: 0.0719 CNY; Weighted Avg Shares: 517,418,332. Balance Sheet: Cash and cash equivalents 1,058,790,000 CNY; Total Assets 1,289,728,000 CNY; Total Liabilities 138,049,000 CNY; Total Stockholders’ Equity 1,151,479,000 CNY. Net Debt: negative 1,057,879,000 CNY (net cash position). Key liquidity ratios: Current Ratio 8.74; Quick Ratio 8.74; Cash Ratio 8.67. Valuation metrics (as of QQ4 2024): Price/Book 0.73x; Price/Sales 8.77x; P/E 5.65x; Enterprise Value/Multiple: -5.23x (negative EV driven by net cash).

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	95.88M	N/A	0.00%
Gross Profit	95.38M	N/A	0.00%
Operating Income	28.76M	113.85%	0.00%
Net Income	37.21M	118.61%	0.00%
EPS	0.07	118.44%	0.00%

Key Financial Ratios

Gross Profit Margin

Excellent

99.50%

Gross profit margin is exceptional, indicating strong pricing power and operational efficiency

Operating Profit Margin

Excellent

30.00%

Operating margin is exceptional, indicating strong pricing power and operational efficiency

Net Profit Margin

Excellent

38.80%

Net profit margin is exceptional, indicating strong pricing power and operational efficiency

Return on Assets

Weak

2.88%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

3.23%

Return on equity suggests inefficient capital allocation

Current Ratio

Strong

8.74

Current ratio indicates excellent liquidity and financial flexibility

Debt to Equity

Conservative

0.00

Debt-to-equity shows conservative leverage and low financial risk

P/E Ratio

Value

5.65x

P/E ratio suggests potential undervaluation or stable earnings

Price to Book

Undervalued

0.73x

Trading below book value, potential value opportunity or distressed

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q2 2025	16.12	-0.05	-66.4%	View
Q1 2025	16.12	-0.05	+122.8%	View
Q4 2024	95.88	0.07	+0.0%	View
Q3 2024	95.88	0.07	+0.0%	View

Genor Biopharma Holdings (6998.HK) Q4 2024 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Financial Highlights

Income Statement

Key Financial Ratios

Management Insights Available for Members

Peer Comparison Available for Members

Investment Outlook & SWOT Available for Members

Historical Earnings Comparison

More 6998.HK Quarterly Reports

6998.HK

6998.HK

6998.HK

Q4 2024 Reports in Healthcare Sector

Related Financial Data

Sector Analysis: Healthcare

6998.HK Full Profile

6998.HK Financial Statements

Earnings Calendar